Trinity Biotech Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Trinity Biotech.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.5%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Mar 02

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Dec 18

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Apr 23

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 01

Trinity Biotech appoints former GE executive Aris Kekedjian as CEO

Oct 03

At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Sep 01

Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M

Jun 30

Returns Are Gaining Momentum At Trinity Biotech (NASDAQ:TRIB)

Jun 14

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 23

Is Trinity Biotech plc (NASDAQ:TRIB) Popular Amongst Insiders?

Feb 25

Trinity Biotech plc (NASDAQ:TRIB) Could Be Less Than A Year Away From Profitability

Feb 02

A Treatise On Trinity Biotech

Jan 13

Did You Miss Trinity Biotech's (NASDAQ:TRIB) Impressive 241% Share Price Gain?

Jan 05

What Do The Returns At Trinity Biotech (NASDAQ:TRIB) Mean Going Forward?

Dec 10

Trinity Biotech (NASDAQ:TRIB) Takes On Some Risk With Its Use Of Debt

Nov 19

Trinity Biotech EPS beats by $0.22, beats on revenue

Nov 17

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Trinity Biotech no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:TRIB - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	57	-37	-14	-12	N/A
9/30/2023	71	-39	-13	-10	N/A
6/30/2023	72	-42	-8	-5	N/A
3/31/2023	74	-34	-7	-2	N/A
12/31/2022	63	-44	-7	-1	N/A
9/30/2022	76	-32	-6	2	N/A
6/30/2022	79	-22	-5	3	N/A
3/31/2022	86	-13	-2	6	N/A
12/31/2021	81	-2	5	13	N/A
9/30/2021	106	-8	11	20	N/A
6/30/2021	116	-2	18	27	N/A
3/31/2021	106	-2	19	29	N/A
12/31/2020	102	-6	14	24	N/A
9/30/2020	91	-20	-1	7	N/A
6/30/2020	83	-27	-6	5	N/A
3/31/2020	90	-31	-2	10	N/A
12/31/2019	90	-29	-6	5	N/A
9/30/2019	94	-30	-4	11	N/A
6/30/2019	93	-29	-7	9	N/A
3/31/2019	95	-23	-7	9	N/A
12/31/2018	97	-23	-10	7	N/A
9/30/2018	97	-39	-10	7	N/A
6/30/2018	99	-40	-8	8	N/A
3/31/2018	99	-40	-6	10	N/A
12/31/2017	99	-39	-7	9	N/A
9/30/2017	98	-36	N/A	8	N/A
6/30/2017	99	-37	N/A	10	N/A
3/31/2017	100	-36	N/A	8	N/A
12/31/2016	100	-39	N/A	10	N/A
9/30/2016	101	3	N/A	17	N/A
6/30/2016	101	16	N/A	14	N/A
3/31/2016	98	16	N/A	13	N/A
12/31/2015	100	22	N/A	13	N/A
9/30/2015	101	23	N/A	15	N/A
6/30/2015	103	15	N/A	17	N/A
3/31/2015	105	17	N/A	16	N/A
12/31/2014	105	15	N/A	16	N/A
9/30/2014	103	18	N/A	8	N/A
6/30/2014	100	10	N/A	6	N/A
3/31/2014	95	10	N/A	8	N/A
12/31/2013	91	10	N/A	9	N/A
9/30/2013	86	9	N/A	15	N/A
6/30/2013	83	17	N/A	17	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de TRIB es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de TRIB crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de TRIB crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de TRIB crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de TRIB crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de TRIB se prevé que sea elevada dentro de 3 años.

Trinity Biotech Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Trinity Biotech plc Provides Revenue Guidance for the Fourth Quarter of 2023

Consensus EPS estimates fall by 47%

Trinity Biotech plc Provides Revenue Guidance for the Third Quarter of 2023

Consensus revenue estimates fall by 17%

Consensus revenue estimates fall by 11%

Consensus EPS estimates fall by 54%

Recent updates

Trinity Biotech Announces the Appointment of Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Full year 2023 earnings released: US$4.82 loss per share (vs US$6.46 loss in FY 2022)

Full year 2023 earnings released

Trinity Biotech plc to Report Q4, 2023 Results on Apr 04, 2024

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

New minor risk - Shareholder dilution

New major risk - Share price stability

Trinity Biotech plc Provides Revenue Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings released

Trinity Biotech to Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya

Trinity Biotech plc Announces CEO Changes

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Trinity Biotech plc Appoints Andrew Omidvar as Director

Consensus EPS estimates fall by 47%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Trinity Biotech plc Provides Revenue Guidance for the Third Quarter of 2023

Trinity Biotech plc to Report Q2, 2023 Results on Oct 03, 2023

Now 20% undervalued after recent price drop

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement

A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Trinity Biotech plc, Annual General Meeting, Sep 29, 2023

Trinity Biotech plc Announces Receives 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System

Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Consensus revenue estimates fall by 17%

New minor risk - Profitability

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Trinity Biotech plc to Report Q1, 2023 Results on Jul 06, 2023

Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Consensus revenue estimates fall by 11%

Full year 2022 earnings: Revenues in line with analyst expectations

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 54%

Trinity Biotech plc to Report Q3, 2022 Results on Dec 15, 2022

Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.037 loss in 2Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released

Trinity Biotech plc Provides Revenue Guidance for the Third Quarter of 2022

Trinity Biotech plc to Report Q2, 2022 Results on Nov 03, 2022

Trinity Biotech Announces Executive Changes

Trinity Biotech Announces the Appointment of Aris Kekedjian as Chairman and CEO

Trinity Biotech appoints former GE executive Aris Kekedjian as CEO

Trinity Biotech plc, Annual General Meeting, Sep 30, 2022

At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M

Trinity Biotech plc to Report Q1, 2022 Results on Jun 30, 2022

Price target decreased to US$4.00

Less than half of directors are independent

Trinity Biotech plc Announces Board Changes

Full year 2021 earnings: Revenues miss analyst expectations

Trinity Biotech plc announced that it expects to receive $25.2 million in funding from MiCo Ltd.

Trinity Biotech plc Announces John Gillard, Group Chief Financial Officer Intention to Resign

Forecast breakeven date pushed back to 2023

Third quarter 2021 earnings: Revenues miss analyst expectations

Second quarter 2021 earnings released

Returns Are Gaining Momentum At Trinity Biotech (NASDAQ:TRIB)

First quarter 2021 earnings released: EPS US$0.077 (vs US$0.11 loss in 1Q 2020)

Trinity Biotech plc Announces the Submission of TrinScreen™ HIV to the World Health Organisation for Approval

Full year 2020 earnings released

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Is Trinity Biotech plc (NASDAQ:TRIB) Popular Amongst Insiders?

New 90-day high: US$6.64

Trinity Biotech plc (NASDAQ:TRIB) Could Be Less Than A Year Away From Profitability

New 90-day high: US$5.08

A Treatise On Trinity Biotech

Trinity Biotech Announces CE Mark of its Covid-19 IgG Elisa Antibody Test

Did You Miss Trinity Biotech's (NASDAQ:TRIB) Impressive 241% Share Price Gain?